ACE2 and COVID-19: We hypothesize that the decrease in circulating levels of ACE2 resulting from both DM and COVID-19 is too great for RAAS inhibitors to fully overcome, that is why the positive effect of RAAS inhibitors may be absent in patients with COVID-19.